Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients

Acta Oto-Laryngologica

Volumn 129, Issue 1, 2009, Pages 4-7

  Scheenstra, Renske J ^a   Rijntjes, Evert ^b   Tavy, Dénes L J ^b   Kingma, Herman ^c   Heijerman, Harry G M ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b HagaZiekenhuis ^*  (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Adult Cystic Fibrosis Centre   (Netherlands)

Author keywords

Aminoglycoside; Cystic fibrosis; Ototoxicity

Indexed keywords

TOBRAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIZZINESS; ELECTRONYSTAGMOGRAPHY; FEMALE; HUMAN; MALE; OTOTOXICITY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING TEST; VESTIBULAR DISORDER; VESTIBULAR TOXICITY;

ADULT; ANTI-BACTERIAL AGENTS; CALORIC TESTS; COHORT STUDIES; CYSTIC FIBROSIS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRONYSTAGMOGRAPHY; FEMALE; HUMANS; MALE; MENIERE DISEASE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; VESTIBULAR DISEASES; VESTIBULE, LABYRINTH;

EID: 58149100773     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480801968534     Document Type: Article

References (15)

1. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156(4 Pt1):1197-204.
2. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67.
3. Aran JM. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg 1995;112:133-44.
4. Darlington CL, Smith PF. Vestibulotoxicity following aminoglycoside antibiotics and its prevention. Curr Opin Investig Drugs 2003;4:841-6.
5. Govaerts PJ, Claes J, van de Heyning PH, Jorens PG, Marquet J, De Broe ME. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990;52:227-51.
6. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987;31:594-9.
7. Proctor L, Petty B, Thakor R, Lietman P, Glackin R, Shimizu H. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope 1987;97:1443-9.
8. Baarsma EA, Rijntjes E. Vestibulo-toxicity of tobramycin. J Laryngol Otol 1979;93:725-7.
9. Aminoff MJ. Electrodiagnosis in clinical neurology. New York: Churchill Livingstone; 1992.
10. Sills AW, Baloh RW, Honrubia V. Caloric testing 2. results in normal subjects. Ann Otol Rhinol Laryngol Suppl 1977;86(5 Pt 3 Suppl 43):7-23.
11. Kingma H. Function tests of the otolith or statolith system. Curr Opin Neurol 2006;19:21-5.
12. Kessler P, Tomlinson D, Blakeman A, Rutka J, Ranalli P, Wong A. The high-frequency/acceleration head heave test in detecting otolith diseases. Otol Neurotol 2007;28:896-904.
13. Duwel P, Ilgner J, Engelke JC, Westhofen M. Subclassification of vestibular disorders by means of statistical analysis in caloric labyrinth testing. Acta Otolaryngol 2004;124:595-602.
14. Chawla N, Olshaker JS. Diagnosis and management of dizziness and vertigo. Med Clin North Am 2006;90:291-304.
15. Mira E. Neuro-otology. Curr Opin Neurol Neurosurg 1991;4:777-82.